Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Theranos Founder Announces New Blood Testing Device

XTALKS VITALS NEWS

Elizabeth Holmes

With Holmes’ impending ban set to take effect on September 5, some had expected her to speak about the validity of the Edison device at the AACC conference.

Tweetables from this article:

Tweet: CEO and founder Elizabeth Holmes unveiled the details of a new blood testing device, called the miniLab http://ctt.ec/0b4f3+CEO and founder Elizabeth Holmes unveiled the details of a new blood testing device, called the miniLab.

Tweet: Theranos' miniLab to analyze small-volume blood samples using multiple different diagnostic methods http://ctt.ec/MlQKb+Theranos' miniLab to analyze small-volume blood samples using multiple different diagnostic methods.

Share this!

August 3, 2016 | by Sarah Massey, M.Sc.

At the American Association for Clinical Chemistry (AACC) conference this week, Theranos CEO and founder Elizabeth Holmes unveiled the details of a new blood testing device, called the miniLab. The device was designed to analyze small-volume blood samples using multiple different diagnostic methods in a single desktop machine.

The device is not yet approved by the US Food and Drug Administration (FDA), however Holmes presented data based on the device’s ability to analyze capillary blood samples at the AACC conference. Holmes recently received a two-year ban from owning and operating a blood testing business from US regulators, after violations were identified at two Theranos testing facilities.

While Theranos’ Edison device was touted as a revolutionary tool with the potential to diagnose multiple conditions from a single drop of blood, the company has since fallen from grace. An inspection of the company’s California testing facility last year – conducted by the Centers for Medicare and Medicaid Services (CMS) – highlighted a number of issues with Theranos’ blood testing practices.



In an effort to find a solution to those concerns, Theranos voided tens of thousands of blood test results which were released between 2014 and 2015. Despite their efforts to make amends, the CMS banned Holmes from the medical laboratory business for two years, and the Newark lab’s certification was revoked.

With Holmes’ impending ban set to take effect on September 5, some had expected her to speak about the validity of the Edison device at the AACC conference. Instead, Holmes discussed the company’s newest miniLab device.

“We’re pleased to share our technologies with the entire laboratory industry,” said Holmes. “It’s the beginning of the next phase of the company, as we introduce our technologies to the world. We also will be working with academic institutions and other independent parties to validate and publish our results.”

Holmes has since faced additional criticism for failing to speak to the inefficiencies in Theranos’ current blood testing methodologies. She has also not provided any peer-reviewed studies on neither the Edison nor the miniLab device.


Keywords: Blood Test, Medical Device, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.